UBS Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-18,392
| Closed | -$327K | – | 8577 |
|
|
2018
Q3 | $327K | Buy |
18,392
+11,883
| +183% | +$204K | ﹤0.01% | 4708 |
|
|
2018
Q2 | $90K | Sell |
6,509
-1,491
| -19% | -$17.7K | ﹤0.01% | 5524 |
|
|
2018
Q1 | $73K | Buy |
8,000
+908
| +13% | +$5.01K | ﹤0.01% | 5452 |
|
|
2017
Q4 | $30K | Buy |
7,092
+1,092
| +18% | +$5.2K | ﹤0.01% | 6248 |
|
|
2017
Q3 | $8K | Sell |
6,000
-380
| -6% | -$529 | ﹤0.01% | 7035 |
|
|
2017
Q2 | $10K | Sell |
6,380
-751
| -11% | -$1.61K | ﹤0.01% | 6807 |
|
|
2017
Q1 | $18K | Sell |
7,131
-9,491
| -57% | -$22K | ﹤0.01% | 6239 |
|
|
2016
Q4 | $42K | Buy |
16,622
+10,622
| +177% | +$30.5K | ﹤0.01% | 5969 |
|
|
2016
Q3 | $19K | Sell |
6,000
-3,099
| -34% | -$9.66K | ﹤0.01% | 6356 |
|
|
2016
Q2 | $29K | Buy |
9,099
+2,649
| +41% | +$9.71K | ﹤0.01% | 5976 |
|
|
2016
Q1 | $20K | Sell |
6,450
-5,606
| -46% | -$18.3K | ﹤0.01% | 6213 |
|
|
2015
Q4 | $48K | Buy |
12,056
+2,010
| +20% | +$9.26K | ﹤0.01% | 5864 |
|
|
2015
Q3 | $47K | Buy |
10,046
+3,946
| +65% | +$20.6K | ﹤0.01% | 5910 |
|
|
2015
Q2 | $32K | Sell |
6,100
-538
| -8% | -$3.23K | ﹤0.01% | 6430 |
|
|
2015
Q1 | $42K | Buy |
6,638
+638
| +11% | +$3.68K | ﹤0.01% | 6225 |
|
|
2014
Q4 | $38K | Buy |
+6,000
| New | +$36.6K | ﹤0.01% | 6838 |
|
Other funds holding ECYT
UBS Group's ECYT Position: Q4 2018 in Review
UBS Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 18,392 shares — an estimated $327K sold.
UBS Group first reported a position in ECYT in Q4 2014 and held it in 16 quarters. The position peaked at $327K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- UBS Group reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- UBS Group sold 18,392 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $327K.
- UBS Group first reported a position in Endocyte, Inc. Common Stock in Q4 2014 and held it in 16 quarters.
- UBS Group's Endocyte, Inc. Common Stock position peaked at $327K in Q3 2018.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on UBS Group's 13F filing for Q4 2018, filed 14 Feb 2019.